RJA
QNTM

Raymond James & Associates’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Raymond James & Associates’s Portfolio QNTM Stock Details QNTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-231
Closed -$1K – 4294
2021
Q4 		$1K Hold
231
– – ﹤0.01% 4124
2021
Q3 		$5K Hold
231
– – ﹤0.01% 4081
2021
Q2 		$3K Hold
231
– – ﹤0.01% 4069
2021
Q1 		$2K Buy
+231
New +$32.3K ﹤0.01% 3981

Other funds holding QNTM

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wolverine Trading
Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Raymond James & Associates's QNTM Position: Q3 2022 in Review

Raymond James & Associates sold out of Quantum Biopharma Class B Subordinate Voting Shares (QNTM) in Q3 2022, closing a stake of 231 shares — an estimated $12K sold.

Raymond James & Associates first reported a position in QNTM in Q1 2021 and held it in 6 quarters. The position peaked at $29K in Q1 2021. 15 funds tracked by Wall St. Rank hold QNTM as of Q3 2022.

  • Raymond James & Associates reported no remaining Quantum Biopharma Class B Subordinate Voting Shares position as of Q3 2022 after selling out during the quarter.
  • Raymond James & Associates sold 231 Quantum Biopharma Class B Subordinate Voting Shares shares in Q3 2022, an estimated $12K.
  • Raymond James & Associates first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q1 2021 and held it in 6 quarters.
  • Raymond James & Associates's Quantum Biopharma Class B Subordinate Voting Shares position peaked at $29K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q3 2022.

Based on Raymond James & Associates's 13F filing for Q3 2022, filed 25 Oct 2022.